Innate Pharma logo

Innate Pharma(IPHA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IPHA

11/13/2026: IPHA (1-star) is currently NOT-A-BUY. Pass it for now.

Innate Pharma is a clinical-stage biotechnology company focused on discovering and developing innovative immunotherapies targeting innate immunity for oncology. The company's main strengths lie in its deep expertise in natural killer cell biology and valuable co-development partnerships with major pharmaceutical players like AstraZeneca. Its primary growth story centers on advancing proprietary platforms like ANKET and expanding clinical indications for lead pipeline assets. Key risks include clinical trial uncertainty, high cash burn, and intense competition within the oncology landscape. The stock is best suited for growth-oriented investors with a high risk tolerance who are willing to monitor clinical readouts and partnership updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveOffers exposure to high-potential clinical biotechnology innovations and lucrative pharmaceutical partnerships.
Momentum investorStrong fit while signal remains positiveStock price movements often react sharply to clinical trial readouts, regulatory updates, and partnership announcements.
Value investorWeak fitThe company lacks stable earnings or traditional valuation metrics due to its clinical-stage status.
Dividend investorWeak fitInnate Pharma does not pay dividends, prioritizing cash retention for clinical trials.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high regulatory, clinical, and price volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings driven by clinical trial updates and news flow.
Valuation riskMedium / highValuation relies heavily on future drug commercialization success and pipeline potential rather than current earnings.
Competition risk (large pharma oncology dominance)HighInnate competes against heavily resourced pharmaceutical companies developing rival immuno-oncology treatments.
Business qualityMediumWhile backed by strong scientific platforms and top-tier partners, clinical uncertainty inherently impacts business predictability.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccess depends on complex clinical trial execution and regulatory navigation.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 154.15M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 24.2K shares
Beta 1.22
52 Weeks Range 1.17 - 2.71
Updated Date 11/15/2026
52 Weeks Range 1.17 - 2.71
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -66.99%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IPHA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, soft company fundamentals, and soft quantitative characteristics.

Company Fundamentals

★★★★★
IPHA has soft overall fundamentals (2 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, moderate earnings growth (+0.6%) is partially offset by weak cash generation (FCF margin -1252.6%), negative revenue growth (-77.9%), weak profitability (net margin -1764.5%).

Financial Health Rating

★★★★★
IPHA's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 2016.9% of revenue). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is IPHA's strongest growth driver at +0.6% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (-77.9%, negative) and free-cash-flow growth (-379.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.4% (soft) and 61.7% of outstanding shares are publicly tradable (solid). Insider ownership of 1.40% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Lion Point Capital, LP 0.07%
Morgan Stanley - Brokerage Accounts 0.04%
SmartHarvest Portfolios, LLC 0.02%
XTX Topco Ltd 0.01%
Citadel Advisors Llc 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
IPHA generates approximately $1,000 of gross profit, $-19,169 of operating income, and $-12,526 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 12.12%

Quantitative Style Profile

★★★★★
IPHA has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Licensing RevenuesUpfront licensing fees, research funding, and clinical milestone payments from strategic pharmaceutical partners like AstraZeneca.Revenue is irregular and tied directly to partnership milestones rather than steady product sales.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 158.40M
Price to Sales(TTM) 15.72
Enterprise Value 158.40M
Price to Sales(TTM) 15.72
Enterprise Value to Revenue 33.88
Enterprise Value to EBITDA -6.94
Shares Outstanding 111.70M
Shares Floating 68.87M
Shares Outstanding 111.70M
Shares Floating 68.87M
Percent Insiders 1.4
Percent Institutions 0.36

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.